ArticlePharmacoEconomics2026

Use and Outcomes of Cost-Effectiveness Analyses and Additional Considerations in Pharmaceutical Reimbursement in the Netherlands.

Diederik Brokkelkamp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.